Inventor · disambiguated record
Minoru Nakamura
Also filed as: NAKAMURA MINORU
29 granted patents·11 pending applications·116 citations·filing 2011–2024
96Inventor score
Top patents by PatentIndex Score
40 records- 0195US9878989B2Heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2016·Granted Jan 30, 2018·7 cites·2 claims
- 0294US9518042B2Nitrogen-containing heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2016·Granted Dec 13, 2016·8 cites·2 claims
- 0394US9499516B2Nitrogen-containing heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2016·Granted Nov 22, 2016·8 cites·2 claims
- 0494US9315458B2Nitrogen-containing heterocyclic compoundTAKEDA PHARMACEUTICAL·Filed 2015·Granted Apr 19, 2016·8 cites·2 claims
- 0593US10610520B2Heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2017·Granted Apr 7, 2020·9 cites·12 claims
- 0693US10323026B2Heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2017·Granted Jun 18, 2019·20 cites·10 claims
- 0793US10087150B2Heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2017·Granted Oct 2, 2018·5 cites·2 claims
- 0892US10428056B2Heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2018·Granted Oct 1, 2019·4 cites·2 claims
- 0991US10548899B2Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activityTAKEDA PHARMACEUTICALS CO·Filed 2016·Granted Feb 4, 2020·7 cites·11 claims
- 1091US9868725B2Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric modulator activity for the treatment of Alzheimer's diseaseTAKEDA PHARMACEUTICALS CO·Filed 2015·Granted Jan 16, 2018·5 cites·16 claims
- 1190US10323027B22,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptorTAKEDA PHARMACEUTICALS CO·Filed 2016·Granted Jun 18, 2019·4 cites·6 claims
- 1290US2024109874A1Nitrogen-containing heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2023·Application pending·0 cites
- 1389US10807987B2Heterocyclic compound and use thereofTAKEDA PHARMACEUTICALS CO·Filed 2019·Granted Oct 20, 2020·5 cites·8 claims
- 1486US10457670B2Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric modulator activity for the treatment of Alzheimers diseaseTAKEDA PHARMACEUTICALS CO·Filed 2017·Granted Oct 29, 2019·2 cites·13 claims
- 1586US9789084B2Nitrogen-containing heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2017·Granted Oct 17, 2017·2 cites·5 claims
- 1686US9789083B2Nitrogen-containing heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2017·Granted Oct 17, 2017·2 cites·5 claims
- 1786US9775827B2Nitrogen-containing heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2017·Granted Oct 3, 2017·2 cites·5 claims
- 1886US9675597B2Nitrogen-containing heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2016·Granted Jun 13, 2017·2 cites·1 claims
- 1986US9662316B2Nitrogen-containing heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2016·Granted May 30, 2017·2 cites·1 claims
- 2086US9655881B2Nitrogen-containing heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2016·Granted May 23, 2017·2 cites·1 claims
- 2185US10899752B22,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptorTAKEDA PHARMACEUTICALS CO·Filed 2019·Granted Jan 26, 2021·1 cites·11 claims
- 2284US11702419B2Heterocyclic compound and use thereofTAKEDA PHARMACEUTICALS CO·Filed 2021·Granted Jul 18, 2023·1 cites·18 claims
- 2384US2022411413A1Nitrogen-containing heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2022·Application pending·0 cites
- 2482US10208046B2Nitrogen-containing heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2015·Granted Feb 19, 2019·4 cites·14 claims
- 2581US9777005B2Bicyclic heterocyclic compound containing a substituted pyrrole ringTAKEDA PHARMACEUTICALS CO·Filed 2013·Granted Oct 3, 2017·5 cites·12 claims
- 2680US11274101B2Heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2018·Granted Mar 15, 2022·1 cites·12 claims
- 2778US11834409B2Heterocyclic NMDA antagonistsTAKEDA PHARMACEUTICALS CO·Filed 2022·Granted Dec 5, 2023·0 cites·22 claims
- 2876US10865200B2Nitrogen-containing heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2018·Granted Dec 15, 2020·0 cites·3 claims
- 2976US2021009572A1Nitrogen-containing heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2020·Application pending·0 cites
- 3069US2018000780A1Nitrogen-containing heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2017·Application pending·0 cites
- 3164US2023002318A1Heterocyclic nmda antagonistsTAKEDA PHARMACEUTICALS CO·Filed 2020·Application pending·0 cites
- 3263US2024309016A1Macrocyclic heterocycle compounds and use thereofTAKEDA PHARMACEUTICALS CO·Filed 2024·Application pending·0 cites
- 3362US2024217957A1Heterocyclic compound and use thereofTAKEDA PHARMACEUTICALS CO·Filed 2023·Application pending·0 cites
- 3457US2014350260A1Heterocyclic compound and use thereofTAKEDA PHARMACEUTICAL·Filed 2014·Application pending·0 cites
- 3554US8901309B2Fused triazoles for the treatment or prophylaxis of mild cognitive impairmentKOIKE TATSUKI·Filed 2011·Granted Dec 2, 2014·0 cites·1 claims
- 3652US8822699B2Heterocyclic compound and use thereofKOIKE TATSUKI·Filed 2011·Granted Sep 2, 2014·0 cites·6 claims
- 3750US2023348435A11-((1h-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2h-imidazol-2-one derivatives and related compounds as gpr139 antagonists for the treatment of e.g. depressionTAKEDA PHARMACEUTICALS CO·Filed 2021·Application pending·0 cites
- 3849US2022289679A1Heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2020·Application pending·0 cites
- 3943US2022089525A1Heterocyclic compound and use thereofTAKEDA PHARMACEUTICALS CO·Filed 2020·Application pending·0 cites
- 4042US11459325B2Heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2019·Granted Oct 4, 2022·0 cites·10 claims
Join the waitlist — get patent alerts
Get an alert when Minoru Nakamura files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →